Tesetaxel

Tesetaxel
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2aS,2bR,3S,4S,6S,8aR,10S,11aS,11bR,13aR)-2a-(acetyloxy)-6-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoyl]oxy}-10-[(dimethylamino)methyl]-4-hydroxy-7,11b,14,14-tetramethyl-2a,2b,3,4,5,6,8a,11a,11b,12,13,13a-dodecahydro-2H-4,8-methano[1,3]dioxolo[3,4]cyclodeca[1,2-d][1]benzoxet-3-yl benzoate;
CAS Number	333754-36-2 ;
PubChem CID	6918574;
ChemSpider	5293771 ;
UNII	UG97LO5M8Y;
CompTox Dashboard (EPA)	DTXSID00870326 ;
Chemical and physical data
Formula	C46H60FN3O13
Molar mass	881.992 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C2[C@@H]3[C@H]([C@@]4(CC[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C6=C(C=CC=N6)F)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)C)O[C@@H](O3)CN(C)C;
	InChI InChI=1S/C46H60FN3O13/c1-24-28(58-40(54)34(52)33(32-27(47)17-14-20-48-32)49-41(55)63-42(3,4)5)21-46(56)38(61-39(53)26-15-12-11-13-16-26)36-44(8,19-18-29-45(36,23-57-29)62-25(2)51)37-35(31(24)43(46,6)7)59-30(60-37)22-50(9)10/h11-17,20,28-30,33-38,52,56H,18-19,21-23H2,1-10H3,(H,49,55)/t28-,29+,30+,33-,34+,35+,36-,37+,38-,44+,45-,46+/m0/s1 ; Key:MODVSQKJJIBWPZ-VLLPJHQWSA-N ;
	(what is this?) (verify)

Tesetaxel is an orally administered taxane being investigated as a chemotherapy agent for various types of cancer, including breast cancer,^[1] gastric cancer,^[2] colorectal cancer,^[3] and other solid tumors.^[4] It differs from other members of the taxane class (e.g. paclitaxel or docetaxel) in that it is administered orally, not intravenously.^[5]

References

^ Clinical trial number NCT01221870 for "Tesetaxel as First-line Therapy for Metastatic Breast Cancer" at ClinicalTrials.gov
^ Evans T, Dobrila R, Berardi R, Sumpter KA, Wall LR, Oyama R, Anthoney DA (June 2006). "A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen". Journal of Clinical Oncology. 24 (18_suppl): 4081. doi:10.1200/jco.2006.24.18_suppl.4081.
^ Clinical trial number NCT00080834 for "DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma" at ClinicalTrials.gov
^ Clinical trial number NCT01315431 for "A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors" at ClinicalTrials.gov
^ Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A (May 2003). "DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo". Cancer Science. 94 (5): 459–66. doi:10.1111/j.1349-7006.2003.tb01465.x. PMC 11160250. PMID 12824894.

Clinical data

ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name (2aS,2bR,3S,4S,6S,8aR,10S,11aS,11bR,13aR)-2a-(acetyloxy)-6-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoyl]oxy}-10-[(dimethylamino)methyl]-4-hydroxy-7,11b,14,14-tetramethyl-2a,2b,3,4,5,6,8a,11a,11b,12,13,13a-dodecahydro-2H-4,8-methano[1,3]dioxolo[3,4]cyclodeca[1,2-d][1]benzoxet-3-yl benzoate
CAS Number	333754-36-2^Y
PubChem CID	6918574
ChemSpider	5293771^N
UNII	UG97LO5M8Y
CompTox Dashboard (EPA)	DTXSID00870326
Chemical and physical data
Formula	C₄₆H₆₀FN₃O₁₃
Molar mass	881.992 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=C2[C@@H]3[C@H]([C@@]4(CC[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C6=C(C=CC=N6)F)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)C)O[C@@H](O3)CN(C)C
InChI InChI=1S/C46H60FN3O13/c1-24-28(58-40(54)34(52)33(32-27(47)17-14-20-48-32)49-41(55)63-42(3,4)5)21-46(56)38(61-39(53)26-15-12-11-13-16-26)36-44(8,19-18-29-45(36,23-57-29)62-25(2)51)37-35(31(24)43(46,6)7)59-30(60-37)22-50(9)10/h11-17,20,28-30,33-38,52,56H,18-19,21-23H2,1-10H3,(H,49,55)/t28-,29+,30+,33-,34+,35+,36-,37+,38-,44+,45-,46+/m0/s1^N Key:MODVSQKJJIBWPZ-VLLPJHQWSA-N^N
^NY (what is this?) (verify)